Companies Bicycle Therapeutics PLC
Bicycle Therapeutics (BCYC): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Bicycle Therapeutics PLC’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $5,540,400FY2023
- $4,857,218FY2024
- $6,341,473FY2025
CEO total pay was $6,341,473 in fiscal 2025, up from $4,857,218 in fiscal 2024.
FY2025: salary $862,339 · bonus $0 · stock awards $1,724,800 · option awards $2,961,297
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Lee | $862,339 | $0 | $1,724,800 | $2,961,297 | $543,642 | $0 | $249,395 | $6,341,473 |
| Chief Executive Officer | ||||||||
| Michael Skynner | 612,471 | 0 | 490,000 | 836,470 | 319,355 | 0 | 68,714 | 2,327,010 |
| Chief Technology Officer (2025); Chief Scientific Officer (effective January 1, 2026) | ||||||||
| Alistair Milnes | 578,189 | 0 | 490,000 | 836,470 | 322,520 | 0 | 65,245 | 2,292,424 |
| Chief Operating Officer (2025); Chief Corporate Development Officer (effective March 17, 2026) | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Kevin Lee | $6,341,473 | $4,857,218 | $5,540,400 | ↑ +1,484,255 |
| Michael Skynner | 2,327,010 | — | — | — |
| Alistair Milnes | 2,292,424 | 2,591,573 | 2,084,264 | ↓ −299,149 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee believes that the most effective compensation program is one that rewards sustainable value creation for our shareholders, by delivering strong company performance, as well as tangible progress towards achieving our mission. The program aims to motivate executive officers to achieve goals by closely linking pay to performance, attract and retain superior individuals using market competitive variable compensation, and align executives' interests with those of shareholders through long-term incentives linked to multi-year strategic goals.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Skynner | OPTION | — | — | — | — | — | $836,470 |
| Alistair Milnes | RSU | — | — | — | — | — | 490,000 |
| Kevin Lee | RSU | — | — | — | — | — | 1,724,800 |
| Kevin Lee | OPTION | — | — | — | — | — | 2,961,297 |
| Alistair Milnes | OPTION | — | — | — | — | — | 836,470 |
| Michael Skynner | RSU | — | — | — | — | — | 490,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Skynner | $490,000 | $0 | $836,470 | 0.0% |
| Alistair Milnes | 490,000 | 0 | 836,470 | 0.0% |
| Kevin Lee | 1,724,800 | 0 | 2,961,297 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael Skynner | Option | 625 | 60.87 | — |
| Michael Skynner | RSU | 938 | — | 6,641 |
| Alistair Milnes | RSU | 938 | — | 6,641 |
| Kevin Lee | Option | 2,084 | 60.87 | — |
| Alistair Milnes | Option | 2,084 | 60.87 | — |
| Kevin Lee | RSU | 3,125 | — | 22,125 |
| Michael Skynner | RSU | 5,469 | — | 38,721 |
| Alistair Milnes | RSU | 5,469 | — | 38,721 |
| Michael Skynner | Option | 9,480 | 29.6 | — |
| Alistair Milnes | Option | 9,480 | 29.6 | — |
| Michael Skynner | RSU | 15,750 | — | 111,510 |
| Kevin Lee | RSU | 17,969 | — | 127,221 |
| Alistair Milnes | RSU | 21,938 | — | 155,321 |
| Michael Skynner | Option | 29,167 | 18.08 | — |
| Kevin Lee | Option | 31,146 | 29.6 | — |
| Michael Skynner | RSU | 35,000 | — | 247,800 |
| Alistair Milnes | RSU | 35,000 | — | 247,800 |
| Alistair Milnes | Option | 40,105 | 18.08 | — |
| Kevin Lee | RSU | 43,313 | — | 306,656 |
| Kevin Lee | Option | 80,730 | 18.08 | — |
| Michael Skynner | Option | 87,000 | 14 | — |
| Alistair Milnes | Option | 87,000 | 14 | — |
| Kevin Lee | RSU | 123,200 | — | 872,256 |
| Kevin Lee | Option | 308,000 | 14 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Pierre Legault, MBA, CPANot independent · Not standing for re-election | $28,695 | $240,365 | $175,000 | $0 | $102,815 | $546,875 |
| Jose-Carlos Gutierrez-Ramos, Ph.DIndependent · Compensation · Nominating and Corporate Governance | 90,000 | 120,183 | 87,500 | 0 | 72,895 | 370,578 |
| Alessandro Riva, M.DIndependent · Audit | 54,173 | 153,484 | 115,000 | 0 | 0 | 322,657 |
| Janice Bourque, MBAIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance · Not standing for re-election | 95,000 | 120,183 | 87,500 | 0 | 1,978 | 304,661 |
| Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCPNot independent · Nominating and Corporate Governance · Partial-year service | 24,715 | 121,733 | 93,250 | 0 | 41,250 | 280,948 |
| Stephen Sands, MBAIndependent · Audit (Chair) · Compensation | 91,981 | 103,713 | 75,502 | 0 | 1,978 | 273,174 |
| Sir Gregory Winter, FRSIndependent · Nominating and Corporate Governance · Not standing for re-election | 65,000 | 120,183 | 87,500 | 0 | 0 | 272,683 |
| Richard Kender, MBAIndependent · Audit · Compensation · Not standing for re-election | 55,539 | 120,183 | 87,500 | 0 | 1,978 | 265,200 |
| Roger Dansey, M.DIndependent · Nominating and Corporate Governance | 22,077 | 116,082 | 89,500 | 0 | 19,200 | 246,859 |
| Felix J. Baker, Ph.DIndependent · Board Chair · Nominating and Corporate Governance | 88,711 | 84,618 | 61,600 | 0 | 0 | 234,929 |
| Herve HoppenotIndependent · Audit · Compensation · Partial-year service | 23,654 | 116,082 | 89,500 | 0 | 0 | 229,236 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | $3 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $639,545 |
| Equity awards (grant-date value) | $1,416,809 |
| All other compensation | $242,094 |
| Total cost of the board | $2,298,448 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Bicycle Therapeutics as a peer
Companies that benchmark against BCYC
9 companies name BCYC as a compensation peer
- Adaptimmune Therapeutics PLCADAPFY2024
- Cogent Biosciences, Inc.COGTFY2025
- Immunocore Holdings plcIMCRFY2025
- MoonLake ImmunotherapeuticsMLTXFY2025
- NOVAVAX INCNVAXFY2025
- Repare Therapeutics Inc.RPTXFY2024
- Syndax Pharmaceuticals IncSNDXFY2025
- Tango Therapeutics, Inc.TNGXFY2025
- Zymeworks Inc.ZYMEFY2025
Each company listed discloses BCYC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BCYC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Bicycle Therapeutics PLC | 2025 | Kevin Lee | $862,339 | $1,724,800 | $2,961,297 | $543,642 | $6,341,473 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 48,748,743 | 785,032 | 163,133 | 98.42% | Passed |
| 2025 | 2025-06-17 | 47,287,428 | 1,743,008 | 104,623 | 96.45% | Passed |
| 2024 | 2024-05-16 | 36,186,115 | 1,202,477 | 9,515 | 96.78% | Passed |
| 2023 | 2023-06-13 | 26,083,084 | 1,965,019 | 8,818 | 92.99% | Passed |
| 2022 | 2022-06-27 | 23,466,799 | 276,755 | 1,801,179 | 98.83% | Passed |
| 2021 | 2021-06-28 | 19,098,902 | 556,551 | 1,969,184 | 97.17% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-17 | 98.42%a |
| 2025 | 2025-06-17 | 96.45%b |
| 2024 | 2024-05-16 | 96.78%c |
a. Approved under the standard stated in the filing — “6 Table of Contents What is an "abstention" and how would it affect the vote? An abstention is not a vote in law and will not be counted in the calculation of the proportion of the votes for or against a particular resolution.”.
b. Approved under the standard stated in the filing — “6 Table of Contents What is an "abstention" and how would it affect the vote? An abstention is not a vote in law and will not be counted in the calculation of the proportion of the votes for or against a particular resolution.”.
c. Approved under the standard stated in the filing — “What is an "abstention" and how would it affect the vote? An abstention is not a vote in law and will not be counted in the calculation of the proportion of the votes for or against a particular resolution.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jennifer Scott Perry | Chief Operating Officer | 2026-07-02 | D | 1,036 | $4 | $4,424 | Common | Form 4 ↗ |
| Travis Alvin Thompson | Chief Financial Officer | 2026-07-02 | D | 819 | 4 | 3,497 | Common | Form 4 ↗ |
| Michael Skynner | Chief Scientific Officer | 2026-07-02 | D | 1,859 | 4 | 7,938 | Common | Form 4 ↗ |
| Kevin Lee | Director | 2026-07-02 | D | 5,905 | 4 | 25,214 | Common | Form 4 ↗ |
| Hannay Michael Charles Ferguson | Chief Prod & Supply Chain Off | 2026-07-02 | D | 1,506 | 4 | 6,431 | Common | Form 4 ↗ |
| Michael Skynner | Chief Scientific Officer | 2026-07-06 | D | 532 | 4 | 2,293 | Common | Form 4 ↗ |
| Kevin Lee | Director | 2026-07-06 | D | 1,737 | 4 | 7,486 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-07-06 | D | 333 | 4 | 1,445 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-07-06 | D | 43 | 4 | 185 | Common | Form 4 ↗ |
| Travis Alvin Thompson | Chief Financial Officer | 2026-07-06 | D | 104 | 4 | 448 | Common | Form 4 ↗ |
| Hannay Michael Charles Ferguson | Chief Prod & Supply Chain Off | 2026-07-06 | D | 255 | 4 | 1,099 | Common | Form 4 ↗ |
| Hannay Michael Charles Ferguson | Chief Prod & Supply Chain Off | 2026-07-15 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Travis Alvin Thompson | Chief Financial Officer | 2026-07-15 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-07-15 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Skynner | Chief Scientific Officer | 2026-07-15 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Lee | Director | 2026-10-02 | D | 6,167 | 3 | 21,399 | Common | Form 4 ↗ |
| Michael Skynner | Chief Scientific Officer | 2026-10-02 | D | 1,942 | 3 | 6,739 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-10-02 | D | 1,094 | 3 | 3,796 | Common | Form 4 ↗ |
| Robert Charles Swanton | Director | 2026-10-02 | D | 3,431 | 3 | 11,906 | Common | Form 4 ↗ |
| Hannay Michael Charles Ferguson | Chief Prod & Supply Chain Off | 2026-10-02 | D | 1,572 | 3 | 5,455 | Common | Form 4 ↗ |
| Travis Alvin Thompson | Chief Financial Officer | 2026-10-02 | D | 893 | 3 | 3,099 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-10-05 | D | 326 | 4 | 1,232 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-10-05 | D | 30 | 4 | 107 | Common | Form 4 ↗ |
| Kevin Lee | Director | 2026-10-05 | D | 1,638 | 4 | 5,848 | Common | Form 4 ↗ |
| Michael Skynner | Chief Scientific Officer | 2026-10-05 | D | 503 | 4 | 1,796 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-10-05 | D | 326 | 4 | 1,232 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-10-05 | D | 80 | 4 | 285 | Common | Form 4 ↗ |
| Hannay Michael Charles Ferguson | Chief Prod & Supply Chain Off | 2026-10-05 | D | 242 | 4 | 864 | Common | Form 4 ↗ |
| Travis Alvin Thompson | Chief Financial Officer | 2026-10-05 | D | 79 | 4 | 282 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (57 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Kevin Lee. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 6,341,473. View filing ↗
- Section 01, Michael Skynner. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 2,327,010. View filing ↗
- Section 01, Alistair Milnes. DEF 14A, filed 2026-04-22. Section “Executive Compensation”. As printed: 2,292,424. View filing ↗
- Section 03, Michael Skynner OPTION. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Alistair Milnes RSU. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Lee RSU. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Lee OPTION. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Alistair Milnes OPTION. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Skynner RSU. DEF 14A, filed 2026-04-22. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-22. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Pierre Legault, MBA, CPA. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 546,875. View filing ↗
- Section 08, Jose-Carlos Gutierrez-Ramos, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 370,578. View filing ↗
- Section 08, Alessandro Riva, M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 322,657. View filing ↗
- Section 08, Janice Bourque, MBA. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 304,661. View filing ↗
- Section 08, Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 280,948. View filing ↗
- Section 08, Stephen Sands, MBA. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 273,174. View filing ↗
- Section 08, Sir Gregory Winter, FRS. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 272,683. View filing ↗
- Section 08, Richard Kender, MBA. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 265,200. View filing ↗
- Section 08, Roger Dansey, M.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 246,859. View filing ↗
- Section 08, Felix J. Baker, Ph.D. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 234,929. View filing ↗
- Section 08, Herve Hoppenot. DEF 14A, filed 2026-04-22. Section “Director Compensation”. As printed: 229,236. View filing ↗
- Section 02, Jennifer Scott Perry 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Travis Alvin Thompson 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Skynner 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Lee 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannay Michael Charles Ferguson 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Skynner 2026-07-06. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Lee 2026-07-06. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Scott Perry 2026-07-06. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Scott Perry 2026-07-06. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Travis Alvin Thompson 2026-07-06. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannay Michael Charles Ferguson 2026-07-06. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannay Michael Charles Ferguson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Travis Alvin Thompson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Scott Perry 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Skynner 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Lee 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Skynner 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Scott Perry 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Charles Swanton 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannay Michael Charles Ferguson 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Travis Alvin Thompson 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Scott Perry 2026-10-05. Form 4, filed 2026-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Scott Perry 2026-10-05. Form 4, filed 2026-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Lee 2026-10-05. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Skynner 2026-10-05. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Scott Perry 2026-10-05. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Scott Perry 2026-10-05. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannay Michael Charles Ferguson 2026-10-05. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Travis Alvin Thompson 2026-10-05. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-18. Item 5.07 · say-on-pay result. As reported: 98.42% (votes for as printed: 48,748,743). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-17. Item 5.07 · say-on-pay result. As reported: 96.45% (votes for as printed: 47,287,428). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-16. Item 5.07 · say-on-pay result. As reported: 96.78% (votes for as printed: 36,186,115). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 639,545 + equity 1,416,809 + all other 242,094 = 2,298,448, summed across the director compensation table rows.
- Bicycle Therapeutics PLC (subject), Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Bicycle Therapeutics PLC's own proxy. As printed: 6,341,473. View filing ↗